Literature DB >> 10782905

Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.

B Hirshberg1, D Shouval, E Fibach, G Friedman, D Ben-Yehuda.   

Abstract

BACKGROUND/AIMS: Hepatic vein thrombosis (Budd-Chiari syndrome) is associated with various hypercoagulable states, such as polycythemia vera (PV), presence of the lupus anticoagulant, paroxysmal nocturnal hemoglobinuria (PNH) and deficiencies of antithrombin III, protein C and protein S. In recent years, it has become evident that patients with the Budd-Chiari syndrome may have more than one risk factor that may cause a state of hypercoagulability. The aim of the current study was to assess the prevalence of occult PV in patients with Budd-Chiari syndrome using a novel method for the detection of spontaneous erythroid growth.
METHODS: Twenty-two patients with Budd-Chiari syndrome were evaluated. As controls, we studied normal donors and four patients with liver cirrhosis and five patients with right-side heart failure, two conditions that in part mimic Budd-Chiari syndrome. The presence of PV was determined by flow cytometric analysis of autonomous growth of erythroid precursors. Patients were considered as having occult PV if they had spontaneous erythroid cell growth in the absence of erythropoietin and with no features of overt PV.
RESULTS: Cells from ten patients with Budd-Chiari syndrome demonstrated spontaneous erythroid cell growth; eight patients (32%) were found to have occult PV and two patients had overt PV. None of the controls had spontaneous erythroid growth. Of the eight Budd-Chiari patients with occult PV, six had one or more additional recognized hypercoagulable states. Seven patients (32%) had protein C deficiency, six patients (27%) had activated protein C resistance, five (23%) had anti-cardiolipin antibodies, five (23%) had antithrombin III deficiency, and four patients (18%) had protein S deficiency. Three patients (14%) were homozygous to methyltetra hydrofolate reductase and ten (45.5%) were heterozygous. One patient had PNH. Overall, in 12 patients there were two or more combined risk factors.
CONCLUSIONS: Using a flow cytometric analysis of autonomous growth of erythroid precursors we found a clear correlation between Budd-Chiari syndrome and occult PV.

Entities:  

Mesh:

Year:  2000        PMID: 10782905     DOI: 10.1016/s0168-8278(00)80218-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Etiology and portal vein thrombosis in Budd-Chiari syndrome.

Authors:  Oguz Uskudar; Meral Akdogan; Nurgul Sasmaz; Sevinc Yilmaz; Muharrem Tola; Burhan Sahin
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 2.  Budd-Chiari syndrome: etiology, pathogenesis and diagnosis.

Authors:  Musa Aydinli; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

3.  Risk factors of thrombosis in abdominal veins.

Authors:  Amit-Kumar Dutta; Ashok Chacko; Biju George; Joseph Anjilivelil Joseph; Sukesh Chandran Nair; Vikram Mathews
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

4.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

5.  Causes of adult splanchnic vein thrombosis in the mediterranean area.

Authors:  Valerio De Stefano; Tommaso Za; Angela Ciminello; Silvia Betti; Elena Rossi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-19       Impact factor: 2.576

Review 6.  Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification.

Authors:  Zeeshan A Wani; Riyaz A Bhat; Ajeet S Bhadoria; Rakhi Maiwall
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.